Phase 3 Celiac Disease Trial · CeD-LA-3002

A prevention-focused Phase 3 trial

First participant expected in the first quarter of 2027.

About the trial

CeD-LA-3002

CeD-LA-3002 is a prevention-focused Phase 3 trial designed to evaluate whether larazotide acetate can protect against gluten-induced intestinal injury and symptoms in adolescents and adults with well-controlled celiac disease. All participants enter the trial with biopsy-confirmed, well-controlled disease and receive a standardized gluten exposure under study supervision, at the upper range of estimated real-world inadvertent intake. The primary endpoint requires participants to maintain both the structure of the intestinal lining and control of symptoms. The trial is expected to enroll its first participant in the first quarter of 2027.

Study designRandomized, double-blind, placebo-controlled, multicenter trial with three parallel arms
ParticipantsApproximately 414 adolescents and adults, ages 12–80, with biopsy-confirmed, well-controlled celiac disease on a gluten-free diet for at least 12 months
LocationUnited States
Treatment period14 weeks of larazotide 0.25 mg, larazotide 0.5 mg, or placebo, taken three times daily before meals, including 12 weeks of standardized gluten exposure
First participant dosingAnticipated in 1Q 2027
Phase 3 timeline: trial start-up 4Q26, first participant dosed 1Q27, Phase 3 execution through 2Q28, data analysis 3Q28, anticipated NDA submission 1Q29

For patients

Information about eligibility and participating sites will be available through ClinicalTrials.gov and the study sites. To register your interest in the study, contact info@interludebio.com.

Patient FAQs

For clinicians and investigators

Clinicians and investigators interested in participating in or referring patients to CeD-LA-3002 can contact us at info@interludebio.com.

Clinical development

Larazotide acetate is an investigational product that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any indication, and its safety and efficacy have not been established.